Gen AI: Transforming Scientific Discovery and Innovation.
Unlocking Potential Across Industries.
Welcome to Silicon Sands News, read across all 50 states in the US and 111 countries.
We are excited to present our latest editions on how responsible investment shapes AI's future, emphasizing the OECD AI Principles. We're not just investing in companies. We're investing in a vision where AI technologies are developed and deployed responsibly and ethically, benefiting all of humanity.
This week, we will explore The Revolutionary Impact of Generative AI on Scientific Discovery.
Let’s Dive Into It . .
TL;DR:
Generative AI is not new—it has been active in scientific fields long before ChatGPT made headlines. However, its recent leaps in performance are now revolutionizing multiple R&D domains, including drug discovery, materials science, climate science, -omics research, and chemistry. By drastically cutting the time needed for experimentation and analysis, generative AI can slash costs, uncover novel breakthroughs, and drive targeted innovation in areas that once required extensive manual labor.
This efficiency shift lowers barriers to entry, allowing both startups and established organizations to pivot more quickly, navigate regulatory complexities, and tap into previously inaccessible market opportunities. For drug discovery, AI helps identify promising targets and candidates within months rather than years. In materials science, generative models reveal optimal crystal structures or properties, accelerating product development. Climate science benefits from robust data integration and real-time simulations, improving policy decisions and sustainability efforts. Meanwhile, -omics research and chemistry gain new abilities to parse enormous datasets—such as protein interactions or chemical pathways—leading to personalized medical interventions or greener manufacturing processes.
For investors, founders, and senior executives alike, the core advantage of generative AI lies in speeding up discoveries, cutting overhead, and guiding R&D toward the most promising pathways. By bridging deep technical expertise with automated modeling and experimentation, generative AI redefines how industries operate, creating competitive advantages and reshaping innovation strategies across the board. Whether it’s through direct investment in AI-focused startups, partnerships that modernize internal workflows, or in-house development of specialized AI teams, decision-makers who embrace generative AI stand to gain both immediate operational efficiencies and long-term market leadership.
Generative AI didn’t materialize out of nowhere in November of 2022 when ChatGPT was released. It had been around in many forms for more than a decade before that. Unlike traditional AI methods that classify or predict based on existing data, generative AI models create new data, designs, or solutions. For non-technical investors, senior executives, and founders, the practical significance lies in how this technology propels breakthroughs across domains such as drug discovery, materials science, climate science, -omics research, and chemistry. These fields hold immense promise for transformative business opportunities and investment returns. When generative AI shortens research and development timelines, it changes industry economics in ways that can yield considerable strategic and financial benefits.
Significant barriers to entry have historically protected hard science disciplines. First, the high level of specialized knowledge required to understand and innovate in these fields has limited access to a select pool of qualified experts. Second, the financial resources needed for experimentation—equipment costs, laboratory space, staff, and materials—can be overwhelming, particularly for startups or smaller institutions. Third, compliance demands and regulatory complexities often draw out development timelines, adding layers of administrative and legal processes that must be managed carefully. Together, these factors have traditionally slowed the pace of innovation and kept discovery cycles long and capital-intensive.
Generative AI transforms this status quo by enabling more rapid proof-of-concept testing, intelligent resource allocation, and earlier identification of promising or unviable pathways. It can reduce startup burn rate, reallocate capital in large enterprises, and open doors for new partnerships that fuse deep science with cutting-edge analytics. While advanced mathematics and sophisticated computer systems underpin generative AI, the essential point for decision-makers is that it offers a powerful toolkit to solve complex scientific problems faster and cheaper.
Below is a look at several critical areas—drug discovery, materials science, climate science, -omics research, and chemistry—where generative AI drives radical changes. The focus remains on explaining its benefits in understandable terms, illuminating risks and opportunities, and clarifying what this technology can do for enterprises and investors.
The current iteration of generative AI that chatGPT and similar models are built on—the transformer architecture and its derivatives have been around since 2017. One of the first areas in which this technology was being experimented was in the hard sciences. So, it's unsurprising that we already see impacts in these fields early in the journey. Generative AI has already delivered tangible results in multiple scientific fields. The technology’s ability to create new solutions and hypotheses rather than merely analyze existing data accelerates discovery, reshaping research foundations. Organizations willing to invest in this approach—and the infrastructure that supports it—are positioned to gain a decisive edge in innovation and market share.
Generative AI’s overarching value proposition is that it lowers barriers to entry. Specialized knowledge is still essential, but AI-driven platforms can guide nonspecialists through early experimental design, bridging the expertise gap. Financial barriers also become more manageable as virtualization reduces the need for extensive lab work until a hypothesis is ready for targeted validation. And though regulatory steps remain crucial, the efficiency gains offered by AI can help companies navigate these processes more smoothly. The evolution of generative AI signals that the most substantial scientific, commercial, and societal breakthroughs are increasingly within reach for a broader range of players.
Are You Ready To Implement AI?
Get results instantly and it’s FREE
Drug Discovery: A Revolution Through Generative AI
Drug discovery has historically been a drawn-out and capital-intensive process. Typical development spans 10 to 15 years and can cost more than $1.4 billion in out-of-pocket expenses, as indicated in reports published by Nature. One reason for this expense is that identifying the correct biological target, designing a drug that effectively interacts with that target, and running clinical trials are highly specialized tasks requiring extensive experimentation. Generative AI offers a disruptive alternative by rapidly searching massive chemical spaces and biological data to find promising targets and molecules.
Companies have already documented notable speed improvements. Some drug candidates have moved from conceptual design to clinical trials in under 30 months, a remarkable reduction compared to traditional timelines that often stretch beyond a decade. Reducing one or two years off this schedule can transform a drug’s commercial viability, especially in competitive therapeutic areas where market exclusivity and first-mover advantages matter. It also lowers the overall R&D costs associated with expensive laboratory work and protracted studies.
Generative AI facilitates target identification, a critical drug discovery task involving uncovering the specific protein or gene that plays a key role in a disease. Platforms such as PandaOmics analyze large-scale datasets—genetic, clinical, and scientific literature—to find pathways or potential targets that researchers might otherwise miss. These platforms also leverage Natural Language Processing (NLP) to scan thousands or even millions of documents, adding depth and speed to the search process.
Molecular design is another area where generative AI has a profound impact. Tools like Chemistry42 combine dozens of algorithms in parallel, virtually generating and screening new compound designs. Instead of synthesizing every candidate in a physical lab, these AI-driven systems propose the most promising designs for real-world testing. This refinement loop ensures that the odds of success are higher when a drug candidate moves to actual chemical synthesis.
Clinical trial optimization is also significantly affected. Generative AI can sift through patient data to predict trial outcomes, helping investigators choose the right cohorts and reducing the probability of expensive trial failures. Some estimates suggest this approach might drop trial costs and durations by about 20%. These figures hold enormous weight for investors, as clinical trials often represent one of drug development's highest-risk, highest-cost phases.
A landmark example is the drug candidate INS018_055. It aims to treat idiopathic pulmonary fibrosis (IPF) and stands out as the first AI-discovered and AI-designed drug to move into Phase 2 trials. The entire development process, from concept to Phase 2, lasted only 30 months. Under a conventional research model, this could have quickly taken more than five years. The drug has shown encouraging efficacy in multiple fibrosis models, and trials are underway in the United States and China.
The financial implications of these technological advances are significant. A McKinsey report suggests that generative AI in the pharmaceutical industry could generate $60–$110 billion in annual economic value. Speeding up time-to-market by one or two years alone can result in meaningful increases in revenue and R&D expenses may drop by as much as 25%. Some hurdles must be navigated, including ensuring high-quality data, validating AI-generated leads through physical testing, and dealing with regulatory requirements. However, the competitive and financial advantages can be transformative for organizations that can overcome these obstacles.
Materials Science: Revolutionizing Discovery and Design
Materials science underpins much modern industry, influencing everything from aerospace engineering to consumer electronics. Discovering new materials or improving existing ones can dramatically reshape manufacturing processes, lower costs, and create new market segments. Traditionally, materials discovery relies on lengthy experimentation because minor tweaks to a material’s structure can produce vastly different performance outcomes.
Generative AI can tackle this challenge by predicting the desired properties of crystal structures or material compositions. Systems like CrystalGRW highlight how machine-learning approaches can suggest the most stable and useful atomic arrangements. Rather than trying hundreds of possibilities in a trial-and-error lab environment, researchers can focus on a targeted group of candidates identified by the AI.
Innovations in generative AI also make engineering materials with particular characteristics possible, often called inverse design. Instead of starting with a set of existing materials and asking what they can do, researchers can start with a target property—a specific thermal conductivity or tensile strength—and let the AI propose the best structural pathways to achieve it. This approach reduces guesswork and expedites the innovation cycle.
Another benefit emerges when AI probes the structure-property relationships inherent in materials. Combining physics-based constraints with machine learning makes it easier to see how minute crystal geometry or composition changes affect overall performance. This process can be integrated with rapid prototyping to validate theories quickly.
A case in point is the MatterGen platform, which merges quantum computing with high-throughput screening. Its objective is to accelerate materials design on a once impossible scale. Large corporations interested in maintaining a technological edge can leverage these advancements to improve supply chains and secure exclusive access to cutting-edge materials.
The economic potential is considerable. Projections suggest the AI-driven materials market could reach $11 billion by 2030, with significant reductions in development costs and shorter time-to-market cycles. For investors and executives, the strategy might involve identifying or partnering with AI startups focused on materials discovery or incorporating these tools into existing R&D pipelines. The payoff can be substantial, especially in industries where material innovation is critical, including renewable energy, consumer electronics, automotive, and aerospace.
Climate Science: AI-Driven Environmental Solutions
Climate science is a vast and urgent field, combining satellite data, ground-based sensors, and historical records spanning decades or centuries. Generative AI offers a new way to synthesize these datasets into actionable insights for policymaking, strategic planning, and investment. One important application lies in improved climate modeling. AI can integrate multiple information streams—such as temperature recordings, precipitation data, and atmospheric measurements—to produce high-resolution simulations in near-real time. This enhanced modeling allows for more accurate predictions of weather patterns and climate change trajectories, including extreme events like hurricanes and heatwaves.
Generative AI is also accelerating the automation of carbon footprint analysis. By consolidating emissions data across supply chains, AI can instantly show where inefficiencies lie and offer suggestions for improvements. Companies benefit by identifying areas that waste energy or generate excessive emissions. They can use these insights to optimize logistics, refine manufacturing processes, or adopt more sustainable energy sources. Real-time monitoring systems make measuring progress on sustainability targets easier, which is increasingly important to investors applying Environmental, Social, and Governance (ESG) criteria.
Another transformative aspect is how AI guides climate mitigation strategies. Generative algorithms can propose configurations that maximize efficiency and stability by modeling renewable energy systems at scale—whether wind, solar, hydro or a combination. This also applies to smart grids, where real-time data from various energy sources are integrated to ensure a consistent supply and demand balance. Resource allocation, be it the distribution of solar panels or the deployment of battery storage systems, can be optimized through simulation, reducing costs for energy developers and boosting returns on infrastructure investment.
Recent developments in generative AI illustrate its unique capacity for prediction and modeling. They build on advanced weather pattern analysis to forecast how changes in one region might ripple through broader ecological systems. By relying on data integration that merges satellite imaging, ground-based measurements, and historical data, climate change impact assessments are becoming more precise and tailored to specific geographic areas. The improved granularity helps policymakers, businesses, and local communities prepare more effectively for challenges like droughts or rising sea levels.
Over the long term, AI-driven climate insights will shape policy support and technological integration. Evidence-based decision-making gains credibility when lawmakers can rely on AI-generated scenarios, helping them weigh risks and develop more potent adaptation strategies. Meanwhile, industries can integrate Internet of Things (IoT) sensor networks and early warning systems that continuously feed data into AI-driven models. This allows timely responses to emergent threats like flooding or wildfires. Combining more accurate predictions, faster data processing, and actionable intelligence can redefine how we address environmental issues, unlocking new investment opportunities in renewables, grid technology, and climate-resilient infrastructure. This convergence of AI and climate science is an increasingly powerful tool for organizations balancing short-term profitability with long-term sustainability goals.
-Omics Research: Transforming Biological Understanding
-Omics research spans genomics (DNA-level data), proteomics (proteins), transcriptomics (RNA transcripts), metabolomics (small molecules involved in metabolism), and multi-omics (combinations of two or more of these fields). These approaches capture the vast complexity of living systems and prove essential for advancing medical research, drug discovery, and personalized healthcare. Modern laboratories generate enormous amounts of data across these domains, yet turning that data into clear, actionable insights remains a significant challenge.
Generative AI plays a pivotal role by integrating multiple -omics data streams—often called multi-omics—into a single, coherent model of biological processes. This integration offers a comprehensive view of how genes, proteins, transcripts, and metabolites interact to drive diseases. Researchers can thus identify biomarkers more directly, discovering molecular indicators linked to a disease’s onset, progression, or severity. With this knowledge, clinicians can diagnose conditions earlier, select better treatment plans, and ultimately reduce clinical and financial burdens on healthcare systems.
In genomics, AI-based sequence analysis quickly processes the output of next-generation sequencing, identifying genetic variants that may predispose individuals to certain diseases or pointing to unknown genes that serve as potential therapeutic targets. In proteomics, generative AI accelerates the prediction of protein structures and their interactions, shedding light on new functions that pharmaceutical companies can exploit for drug design. In metabolomics, AI uncovers biochemical footprints that reveal how a disease alters normal metabolic pathways, offering unique insights for potential interventions. The crucial addition of multi-omics integrates all these layers—genetic, proteomic, transcriptomic, and metabolic—allowing researchers to pinpoint the precise mechanisms driving complex diseases.
The synergy with drug discovery becomes particularly compelling when generative AI identifies novel biological targets from multi-omics data. That information feeds directly into AI-driven drug design and optimization pipelines, reducing the initial investigative phases that would otherwise consume valuable R&D resources. Another key advantage is patient stratification in clinical trials. By matching newly discovered biomarkers to specific patient subgroups, researchers increase the likelihood that treatments will be tested in the individuals most likely to benefit from them, improving trial outcomes and reducing overall cost.
From a business perspective, organizations harnessing multi-omics successfully are poised to become frontrunners in personalized medicine. Investors and stakeholders watch closely for biotech firms demonstrating excellence in integrated —omics approaches, as breakthroughs in this domain often signal advanced capabilities in tackling diseases at a systemic level. Although the path can be complex—requiring careful data collection, management, and analytic expertise—those willing to invest in and master multi-omics stand to redefine the future of precision healthcare. By capturing the intricate interplay of genomic, proteomic, transcriptomic, and metabolic factors, these companies lay the groundwork for innovations that can reshape medical treatment and deliver substantial returns for those who support them.
Chemistry: AI-Driven Transformation of the Chemical Sciences
Chemistry underpins pharmaceuticals, petrochemicals, agriculture, consumer goods, and advanced manufacturing industries. The traditional approach to discovering new chemical compounds, catalysts, or processes often involves high resource expenditure and extensive trial and error in the lab. Generative AI can significantly shorten these laborious processes by modeling the outcome of chemical reactions or suggesting new molecules with desired properties before running a single experiment.
One breakthrough is in molecular design and generation. AI can propose novel molecule structures that exhibit specific properties, such as increased solubility or enhanced stability. The advantage comes from searching through “chemical space” (the vast universe of possible molecules) methodically rather than randomly. Generative models inform researchers which molecules are most promising to synthesize in reality.
Synthesis planning and optimization are also game-changers. By analyzing extensive reaction databases, AI can predict efficient synthetic routes that minimize byproducts, reduce the need for expensive reagents, and shorten reaction times. This helps smoothly scale a process from the lab bench to commercial production. For businesses, the cost savings and time reductions accumulate quickly, opening up new areas of specialty chemicals with potentially unique applications.
Chemical space exploration takes on new significance when generative AI can capture subtle structure-activity relationships. These relationships govern how a given molecule will behave under different conditions and how it might interact with other substances. By generating and testing a broad range of candidates in silico, researchers have a more refined view of where to focus practical lab work.
There are compelling real-world illustrations of AI's impact on chemistry. Some labs now operate microfluidic systems that test multiple chemical reactions simultaneously, guided by AI algorithms that adjust parameters in real-time. Robotic platforms further automate these steps, ensuring continuous experimentation without the limits of human working hours. This “autonomous chemical research” paradigm streamlines the process of discovering new reagents, catalysts, or compounds.
Market forecasts indicate that AI-driven chemistry could reach $2.29 billion by 2030, reflecting substantial reductions in R&D costs and faster product launches. Companies that adopt these practices early have a competitive edge, particularly in specialty areas requiring advanced chemistry solutions. However, technical, regulatory, and data quality concerns must be managed, along with the need for specialized talent. Nonetheless, the combination of AI and chemistry redefines how science is practiced.
Convergence and the Larger Business Picture
These diverse scientific domains—drug discovery, materials science, climate science, omics research, and chemistry—appear distinct but gradually converging. Insights from materials science can feed into green energy solutions that address climate challenges, while improvements in chemistry can accelerate drug development. The central role of generative AI is to reduce the time between hypothesis and validation, consistently improving the quality of outcomes while lowering costs.
The overarching message for corporate executives, founders, and investors is that generative AI can embed enormous value within existing and future businesses. Pharmaceuticals gain from shorter development times and more accurate clinical trials; manufacturers benefit from designing superior materials; energy projects become more sustainable and efficient; and healthcare transitions into a data-driven paradigm. The shift is broad and rewrites the rules of how entire sectors operate.
From an investment standpoint, the rise of generative AI in scientific research points to multiple avenues for returns:
VC funds can back early-stage companies specializing in domain-specific AI platforms.
Private equity can amplify the capabilities of more mature firms by investing in AI-driven R&D expansions.
Corporate venture arms can take strategic stakes in startups that align with longer-term innovation goals.
There are important strategic considerations for companies interested in this space. Some may build an in-house AI team to tailor models to specific needs. Others may form partnerships with specialized AI firms. In both scenarios, rigorous data governance, strong information security, and careful attention to regulatory guidelines will be essential.
Regulatory bodies worldwide are beginning to adapt their frameworks to AI-driven methods. This is especially relevant in sensitive areas like drug discovery or environmental policy, where the stakes are high. Forward-thinking organizations are engaging with regulators early to help shape practical standards for AI validation.
Risk management cannot be ignored. Though AI can reduce the risk of misguided experimentation, it brings challenges related to data privacy, algorithmic bias, and cybersecurity. There is also the risk of overreliance on automated processes at the expense of human expertise. Therefore, Companies must strike a thoughtful balance, ensuring that AI is a robust tool without eclipsing critical human oversight.
From Hype to Tangible Results
While AI hype can sometimes outpace practical reality, generative AI applications have already moved beyond pilot stages in several research domains. Organizations are achieving measurable gains in efficiency and innovation, and the consensus in many expert circles is that improvement will likely accelerate as AI models integrate quantum computing and ever-more sophisticated simulations.
Generative AI’s overarching impact on scientific discovery stems from its ability to handle complexity, generate new hypotheses, and direct research toward the most promising avenues. For business leaders, this technology provides value whenever it supports a faster track to breakthroughs and reduces the number of dead ends. Even incremental gains in these areas can result in significant long-term advantages, from cost savings to novel products that shape future markets.
Bringing generative AI into large organizations often requires cultural changes. Research teams accustomed to manual experimentation may worry about job displacement, while others may question the reliability of AI-driven findings. Transparent collaboration between technical teams and domain experts can mitigate these concerns. When employees become co-creators rather than passive recipients of AI outputs, the organization can share the benefits of the new technology.
Seizing the Generative AI Opportunity
Generative AI stands at the intersection of advanced computing and groundbreaking scientific innovation. Its potential to shorten development cycles, reveal hidden opportunities, and improve cost efficiency is transforming industries' operations—the drug discovery field benefits from dramatically shorter timelines and more accurate clinical trials. Materials science is scaling new heights by creating and testing high-performance materials. Climate science is forging better predictive models integrating multiple data sources to guide policy and investment. -Omics research is unraveling the intricacies of human biology, paving the way for more targeted medicine. Chemistry is becoming far more agile, enabling manufacturing, pharmaceuticals, and environmental solutions breakthroughs.
Investors, founders, and senior executives must be aware of generative AI rather than consider it a luxury. Understanding its capabilities, applications, and limitations can guide strategic choices, influence R&D investments, and shape competitive advantage. The technology is not a panacea, nor is it entirely free of risk, but it promises to reimagine what is possible in scientific discovery.
Whether through direct investment in AI-centric startups, partnerships that integrate AI workflows into existing business processes, or in-house innovation labs, a thoughtful approach to generative AI can drive short-term and long-term gains. The benefits range from immediate operational efficiencies to the emergence of new revenue streams. In a world where success often hinges on being the first to innovate effectively, generative AI allows business leaders to align themselves with the most transformative possibilities in science and technology.
Organizations that engage with generative AI today will likely set the pace for their industries tomorrow. Strategic foresight and a willingness to invest in AI-driven research can open pathways to growth in competitive markets, delivering impact beyond next-quarter results to shape innovation contours over the coming decades. By bridging advanced algorithms with pressing scientific and industrial challenges, generative AI stands poised to redefine how research is conducted, how products are created, and how companies compete globally.
Key Takeaways
For LPs
The expanding scope of generative AI in hard science domains can diversify your portfolio beyond traditional tech, offering exposure to industries like pharmaceuticals, advanced materials, and climate solutions that leverage AI for accelerated R&D.
Early adoption of these AI-driven scientific breakthroughs can produce above-average returns, particularly when companies reduce costly experimentation cycles and time-to-market.
Conducting ongoing due diligence on fund strategies is critical. Assess whether managers have the right technical advisors and partnerships to navigate regulatory complexities and validate AI-generated discoveries.
For VCs
Focus on startups that exploit generative AI to solve high-value scientific problems. Companies that use AI to enable drug discovery, materials innovation, or climate modeling can often command premium valuations and present sizable exit opportunities.
Cultivate cross-disciplinary expertise within your portfolio. Founders who combine AI proficiency with domain knowledge in biology, chemistry, or engineering are positioned to capitalize on fast-evolving markets.
Monitor data access and quality closely. The best generative AI startups often form strategic partnerships with institutions or corporations to secure proprietary data. This data moat can serve as a durable competitive advantage.
For Senior Executives
Generative AI can significantly shorten R&D timelines and lower costs, freeing up capital for innovation and expansion. Integrating AI-led workflows may be critical in staying competitive across drug development, manufacturing, and sustainability.
A measured approach to AI adoption is essential. Balancing algorithmic automation with human oversight can mitigate risks such as biased results, data breaches, and regulatory hurdles—particularly in tightly regulated sectors like healthcare and energy.
Proactive collaboration with regulators and stakeholders can ease the entry of AI-derived solutions into the market. Engaging early to align validation processes and compliance standards helps avoid costly delays.
For Founders
It is paramount to demonstrate proof of concept quickly. Generative AI’s power lies in accelerating testing and experimentation, so focusing on rapid prototypes or pilot projects can help secure follow-on funding and partnerships.
Building or partnering to obtain robust data pipelines is crucial. Effective AI models thrive on high-quality, domain-specific data, so nurturing relationships with research institutions or industry collaborators is often a prerequisite for success.
Consider regulatory pathways from the outset. Whether in healthcare, materials, or climate tech, understanding how AI-driven discoveries will be validated and approved can define your go-to-market strategy and significantly impact investor interest.
In this era of AI advancement, the most successful ventures will be those that can adeptly navigate the nuances of model selection, data transparency, and licensing restrictions. By carefully weighing these factors and prioritizing ethical considerations, we can work towards an AI future that is not only technologically advanced but also responsible and inclusive.
The journey towards truly open, responsible AI is ongoing. We will realize AI's full potential to benefit society through informed decision-making and collaborative efforts. As we explore and invest in this exciting field, let’s remain committed to fostering an AI ecosystem that is innovative, ethical, accessible to all, and informed.
I would like to recommend the SubStack I read by Bernardt Vogel.
Qantm AI provides guidance on AI strategy and governance based on an approach developed over a decade of transforming Fortune 500 companies and creating tens of billions of dollars of value for them. We also provide education for senior leaders and various advisory services for private equity and venture capital firms.
UPCOMING EVENTS:
NASA GSFC 2ND AI SYMPOSIUM
Synergies Across Multiple Domains: Shaping the Future of AI,
Washington D.C. 25 Jan ‘25
Metro Connect USA 2025 Fort Lauderdale FL 24-26 Feb ‘25
2025: Paris, Milan, Romania, Hong Kong, Dublin, Munich, New Delhi, Netherlands
Join 1000s of investors & startups at the Early-Stage Virtual Conf on Jan 30! 128 VCs, Family Offices, & angels committed to 1:1 Speed Pitch meetings with startups during the event alongside panels on VC trends 2025, how Family Offices invest in VC funds and startups, & best fundraising practices. Register for free
This conf helps investors: 1) become value-added investors by exploring those startups that need support beyond money, 2) add 1-3K startups in your funnel, & 3) find co-investors for your SPVs.
This conf helps startups to connect with active investors in your sector/vertical & finish your fundraising campaign.
More speakers/topics on the website. JAN 30, RSVP:
RECENT PODCASTS:
🔊 BetterTech, hosted by Jocelyn Houle. LIVE ON December 4, 2024
🔊 AI and the Future of Work published November 4, 2024
🔊 Humain Podcast published September 19, 2024
🔊 Geeks Of The Valley. published September 15, 2024
🔊 HC Group published September 11, 2024
🔊 American Banker published September 10, 2024
Unsubscribe
Finding a convenient way to link it up took me a while, but here's how to get to the unsubscribe. https://siliconsandstudio.substack.com/account